ENCePP web header
ENCePP web header

  • Ruthsarian
  • Home
  • Sitemap
  • Q & A
  • Notice Board
    • PhEpi & PhV activities
    • Research Funding
    • Conferences & meetings
    • Recruitment
  • Links
  • Contact Us

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Pattern of use of incretin-based drugs in clinical practice Dr Roberto Giuseppe 14/02/2019
Finalised Surveillance of Adverse Event related to childhood vaccination reported by parents Professor Moretti Ugo 12/02/2019
Ongoing Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU Professor Saad Shakir 02/09/2019
Planned The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases Professor Jesper Hallas 07/10/2020
Planned Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines Dr Caitlin Dodd 22/09/2020
Planned Time to treatment intensification in patients receiving metformin+incretin-based medicines versus metformin+other hypoglicemics Dr Roberto Giuseppe 14/02/2019


  • News
  • About Us
  • ENCePP Documents
  • Training in PhEpi and PV

  • Code of Conduct
  • Standards & Guidances
  • ENCePP Study Seal
  • Public Consultation
  • Glossary of terms

  • Resources Database

  • Partners forum

  • EU PAS Register

  • About EU PAS Register

© 1995-2020 European Medicines Agency | Contact Us | Privacy Policy | Admin Login | Disclaimer

As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period.


combined emea eu logo European Medicines Agency Europa Website
Version: 4.4.1.1